Content of review 1, reviewed on October 17, 2016

Reviewer Confidential Comments to Editor Review Sheet: General Judgement ============================================================

  1. Is the paper acceptable for publication
         (a)    in its present form?
    
         (b)   with minor revisions?
    

Should the paper be reconsidered after major revision?

Is it unacceptable for publication?

  1. Please list any other general comments or specific suggestions in the separate blind comments to author's box.

I recommend the editor to publish the article with minor revisions, since it is an interesting paper, which adds knowledge in its specific field, well organized and logically developed. The writing style is quite satisfactory, i.e. grammatically correct and easy to understand but I will recommend to do some minor revisions. Reviewer Blind Comments to Author a) introduce briefly a sentence about A549 cell line and the reason of use it (in the Introduction section, not just in the Discussion section; resume it in discussion section); b) in Introduction section (beginning of the 3rd paragraph) change “Stains” to “Statins”; c) remove the LAC abbreviation, since it is so little used (twice?); d) define ERK in Introduction section; e) in Discussion section review/improve the connection of the sentence on the ERK with the following "Classical MAP kinases ..." (or explain it better); f) “...that are involved in functions, including the regulation...” consider changing to “...that are involved in several functions, including the regulation...”; g) remove coma from “...mitosis, and postmitotic functions...”; h) remove coma from “...carcinogenesis, and cancer progression...”; i) change TGF-â to TGF-α; j) remove coma from “...’cadherin switching’, and cell migration.”; k) remove coma from “...expression, and enhance...”; l) remove coma from “...pathway, and may be...”;

Source

    © 2016 the Reviewer (CC BY 4.0).

References

    Li, S., Shu-Shan, J., Hai-Ming, J., Hua, W., Wen-Hua, X., Chang-Jun, L. 2015. Simvastatin downregulates expression of TGF-beta RII and inhibits proliferation of A549 cells via ERK. Tumor Biology.